Share this article

Spine and orthopaedics company Orthofix Medical has commercially introduced its WaveFormL lateral lumbar interbody system in the US.

Featuring a porous structure, the 3D-printed device has been developed to be used in lateral lumbar interbody fusion (LLIF) procedures.

WaveForm L is engineered with a repeating wave-like structure. This design efficiently distributes compressive loads and offers high porosity, thereby maximising stiffness without sacrificing strength.

As WaveForm L has 80% body porosity, it can improve imaging characteristics and enhance graft packability.

Meanwhile, the wave-like structure’s optimised 65% endplate porosity promotes bone ingrowth and ensures early mechanical stability.

Orthofix Global Spine president Kevin Kenny said: “We are dedicated to providing a comprehensive portfolio of innovative, procedurally focused products strategically designed to work together to drive fusion.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“WaveForm L represents the latest advancements in proprietary spinal implant technology engineered to address the many nuances of spinal pathology to meet individual patient needs, delivering both clinical and economic value to patients, surgeons and hospital systems.”

LLIF procedures constitute roughly 20% of the interbody device market.

This month, Orthofix Medical obtained the US Food and Drug Administration 510(k) clearance for its advanced bioactive synthetic graft, OsteoCove, for use in spine and orthopaedic procedures.

The company also announced the full commercial launch of the graft, which has been formulated to deliver better bone-forming capabilities to support a wide range of spine and orthopaedic procedural applications.